<DOC>
	<DOCNO>NCT01163526</DOCNO>
	<brief_summary>A research study liver perfusion ( blood flow liver time ) . We hope learn whether perfusion characteristic liver mass may predictive response treatment whether liver perfusion characteristic use follow response treatment .</brief_summary>
	<brief_title>Perfusion CT Predictor Treatment Response Patients With Hepatic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>3.1.1 Patients suspect biopsyproven liver mass include unresectable hepatocellular carcinoma ( HCC ) , unresectable colon cancer metastases liver , metastatic neuroendocrine tumor liver eligible enrollment . 3.1.2 Patients undergone prior chemotherapy one year prior study eligible enrollment . 3.1.4 Patients must 18 year old . Patients must pregnant , childbearing age , must take precaution become pregnant . 3.1.5 No life expectancy restriction . 3.1.6 ECOG Karnofsky Performance Status employ . 3.1.7 Patients renal failure ineligible study ( Glomerular filtration rate ( GFR ) must &gt; 60 ) 3.1.8 Ability understand willingness sign write informed consent document . 3.2.1 Patients undergone prior chemoembolization hepatocellular carcinoma ( HCC ) ineligible enrollment . Patients undergone chemotherapy within one year prior study also ineligible enrollment . 3.2.2 No restriction regard use investigational agent . 3.2.3 Patients severe contrast allergy ineligible . 3.2.4 Patients pregnant try become pregnant exclude study . 3.2.5 Patients cancer survivor Human Immunodeficiency Virus ( HIV ) positive exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>